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Abstract. Forty-three anxiety disorder patients (DSM-III) who completed the 
Hopkins Symptom Checklist (XL-90-R) and a caffeine questionnaire were 
compared to 124 medical inpatients. Eighty-four percent of the anxious patients 
were low caffeine consumers (O-249 mg/day) compared to 41% of medical 
inpatients; 65% of anxiety patients consumed < 100 mg/day. In anxiety patients, 
there were no significant correlations between subscale scores of the XL-90-R and 
amount of caffeine consumption. Patients who consumed < 100 mg/day did not 
differ on anxiety subscale scores of the SCL-90-R from those who consumed more. 
However, patients who reported becoming anxious in response to drinking coffee 
had higher SCL-90-R anxiety subscale scores than patients who did not, even 
though their daily consumption was not different. It appears that anxiety disorder 
patients have increased caffeine sensitivity which leads to decreased consumption. 
Key Words. Caffeine, anxiety disorders. 
Caffeine is known to produce anxiety (Greden et al., 1978; Gilliland and Andress, 
1981; Rapoport et al., 1981; Victor et al., 1981) and even panic attacks (Uhde et al., 
1984). In normal adults (Gilliland and Andress, 1981) and psychiatric inpatients 
(Greden et al., 1978), state and/ or trait anxiety scores were higher in moderate to high 
caffeine consumers, and in medical inpatients (Victor et al., 1981) and normal adults 
(Rapoport et al., 198 l), high caffeine consumers were more sensitive to caffeine intake 
(i.e., became anxious), However, somatic symptoms seem to be reported more 
frequently in low consumers (Victor et al., 1981; Rapoport et al., 1981). Boulenger et 
al. (1984) reported a significant positive correlation between trait anxiety and daily 
caffeine consumption, and increased sensitivity to caffeine in panic disorder patients 
but not in normal controls or patients with a major depressive disorder, even though 
daily caffeine consumption was not significantly different between these groups. 
Pharmacologically, caffeine has been reported to antagonize some of the effects of 
benzodiazepines (Pole et al., 1981; File et al., 1982; Mattila et al., 1982) and to block 
benzodiazepine and adenosine receptor binding (Boulenger et al., 1982; Snyder and 
Sklar, 1984). Acute administration of caffeine increases blood pressure, and plasma 
and urinary catecholamines (Robertson et al., 1978; Patwadhan et al., 1980) as well as 
plasma cortisol concentration (Uhde et al., 1984) but chronic administration does not 
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increase plasma and urinary catecholamines (Robertson et al., 1981). Caffeine also 
increased norepinephrine utilization associated with decreases in /3-adrenergic 
receptors in rat forebrain (Goldberg et al., 1982). 
Perhaps because of these pharmacological actions, anxiety disorder patients seem 
to consume less caffeine or even stop consuming caffeine to avoid intensification of 
anxiety. Boulenger et al. (1984) suggested that the positive correlation they observed 
between trait anxiety and caffeine consumption was not due to patients’ “self- 
treatment,” a pattern that has been reported for some depressed patients and for some 
people with caffeine-withdrawal headache (Greden et al., 1978,198O). Thus, in anxiety 
disorder patients, it is possible that the relationship between daily caffeine 
consumption and level of anxiety may be different from those previously reported for 
normal adults, and medical and psychiatric inpatients. We examined these issues 
further in anxiety disorder patients, hypothesizing that anxious individuals would 
have lower daily caffeine consumption and be more sensitive to the anxiety-provoking 
effects of caffeine than other people. 
Methods 
Forty-three outpatient subjects who met DSM-III (American Psychiatric Association, 1980) 
criteria for anxiety disorder completed the Hopkins Symptom Checklist (SCL-90-R) (5-point 
scale: 0 q “not at all” through 4 = “extremely”) (Derogatis, 1977) and a caffeine questionnaire 
designed by one of us (J.F.G.).The questionnaire assessed amount of daily consumption of 
caffeine-containing beverages and drugs, symptom profiles in response to drinking a cup of 
coffee (see Table I), and use of minor tranquilizers and other medications; details of this 
questionnaire have been reported elsewhere (Victor et al., 1981). Amount of daily caffeine 
consumption from approximately 25 sources was calculated, and correlations between caffeine 
Table 1. Symptom profile comparison between anxiety disorder patients and 
medical inpatients, and between < 100 mg and z- 100 mg groups of anxiety 
disorder patients 
Anxiety Medical Anxiety disorders 
Symptoms 
disorders1 inpatients1 
(n = 34) (%) (n = 51) (O/o) 
cl00 mg >lOO mg 
(n = 25) (%) (n = 14) (O/o) 
Anxiety 64.7 21.52 72.0 50.0 
Diarrhea 11.6 16.5 12.0 14.3 
Diuresis 73.5 59.5 72.0 78.6 
Headache 9.1 13.0 12.0 7.1 
Lightheadedness 23.5 13.9 28.0 14.3 
Palpitation 35.3 25.3 40.0 28.6 
Stomach pain 23.5 27.8 24.0 21.4 
Spot in front of eye 2.9 3.8 4.0 7.1 
Tachycardia 44.1 28.2 60.0 28.63 
Tachypnea 23.5 12.4 28.0 28.6 
Tremulousness 35.3 16.44 44.0 14.3 
In order to make groups comparable, only low conwmer~ !< 250 mg/day) are included 
2. x2 = 16.75, < 0.001. p 
3. x2 = 4.01, < 0.05. p 
4. x2 = 4.36, c 0.05. p 
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consumption and subscale scores on the SCL-90-R were examined. Student’s t test (two-tailed) 
was used to compare mean differences between patient groups. Medical inpatients (n q 124) who 
responded to the same caffeine questionnaire and who were free from any known psychiatric 
illness or treatment (data for this group were reported previously by Victor et al., 1981) were 
compared with the anxiety patients (by ~2) in distribution of daily caffeine consumption and 
reported symptom profiles in response to drinking a cup of coffee. 
Results 
Demographic Data and Caffeine Consumpion. Theanxiety patients included 16 
males and 27 females. Their mean age was 34.4 (SD 10.0) years. Diagnostically, 34 had 
panic disorder or agoraphobia with panic attacks (PA group); the remaining nine 
included six with obsessive-compulsive disorder or generalized anxiety disorder, and 
three with simple or social phobia (non-PA group). Mean daily caffeine consumption 
of all anxiety patients was 141.7 (SD 215.7) mg/day. Distribution of daily caffeine 
consumption showed that 28 patients (65%) consumed G 100 mg/day (roughly 
equivalent to one cup of coffee), five (12%) consumed 100-199 mg/day, four (9%) 
consumed 200-299 mg/day, and six (14%) consumed > 300 mg/day. Daily caffeine 
consumption did not differ between PA and non-PA groups (137.4 f SD 218.2 
mg/day for PA vs. 158.2 f SD 217.8 mg/day for non-PA. t = 0.26, NS). 
Responses to Drinking a Cup of Coffee. Thirty-nine anxiety patients completed 
this item (30 were PA, nine were non-PA). In the total sample, order of frequency of 
symptoms in response to a cup of coffee were diuresis (74%), anxiety (64%), 
tachycardia (49%), palpitations (36%) and tremulousness (33%). Twenty-five patients 
responded that a cup of coffee made them anxious. Among them, 23 were PA and 2 
were non-PA; this difference was significant (x2 = 10.30,~ < 0.001). 
Anxiety patients were divided into two groups-< 100 mg/day vs. > 100 mg/day of 
caffeine consumption. A 100 mg cutoff was used because this is the amount contained 
in approximately one cup of coffee. Symptom profiles were compared between the < 
100 mg and the > 100 mg groups. Frequency of developing anxiety was not different 
between groups (~2 = 1.94, NS), but somatic symptoms such as tachycardia, 
palpitation, tremulousness, and lightheadedness tended to develop more in the < 100 
mg group, and tachycardia reached statistical significance (Table 1). 
Daily Caffeine Consumption and the SCL-90-R. There were no significant 
correlations between amount of daily caffeine consumption and any of the subscale 
scores of the SCL-90-R. To compare mean score differences of the SCL-90-R, subjects 
were divided in two different ways: (1) < 100 mg group vs. > 100 mggroup (as above); 
and (2) development of anxiety in response to coffee consumption (caffeine-sensitive 
group vs. caffeine-nonsensitive group). There were no differences in mean SCL-90-R 
subscale scores between the < 100 mg group and the > 100 mggroup. However, when 
subjects were divided by response to caffeine consumption, the caffeine-sensitive 
group had significantly higher SCL-90-R subscale scores in somatization, anxiety, 
and phobic anxiety than the caffeine-nonsensitive group (Table 2). There were no 
differences in caffeine consumption or use of minor tranquilizers between these 
groups. 
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Table 2. SCL-90-R differences between caffeine-sensitive and caffeine- 
nonsensitive group in total sample and in PA group 
Total patients (n = 39) PA group only (n = 30) 
SCL-90-R Caffeine- Caffeine- Caffeine- Caffeine- 
Scales sensitive nonsensitive sensitive nonsensitive 
(mean + SD) (n = 25) (n = 14) (n = 23) (n = 7) 
Somatization 1.46 + 0.68 0.82 f 0.701 1.56 + 0.61 1.19 + 0.73 
Obsessive- 
compulsive 1.72 t- 0.74 1.49 f 0.84 1.75 + 0.76 1.53 t 0.79 
Interpersonal 
sensitivity 1.83 + 0.90 1.61 zk 1.03 1.82 k 0.87 1.44 L 0.83 
Depression 2.02 * 0.75 1.83 + 0.91 2.07 + 0.73 1.87 !I 0.89 
Anxiety 2.45 f 0.73 1.69 f 0.982 2.51 + 0.67 1.83 +_ 0.833 
Hostility 1.10 ?z 0.83 1.20 + 0.85 1.13 If- 0.86 1.12+0.91 
Phobic anxiety 2.19 rt 0.84 1.39 2 0.104 2.28 +_ 0.82 1.80 I? 0.90 
Paranoid ideation 1.20 +_ 0.94 1.04 + 0.84 1.20+_0.95 0.93 ?I 0.98 
Psychoticism 1 .oo ?C 0.57 0.91 + 0.72 1.90 S 0.56 0.89 + 0.76 
Global severity 
index 1.68 t 0.53 1.34 + 0.70 1.72 rt 0.52 1.42 2 0.71 
Positive symptom 
distress index 2.39 F 0.54 2.10 +_ 0.59 2.43 + 0.52 2.03 + 0.53 
1. r= 2.79, <O.Ol. p 
2. t= 2.76, < 0.01. p 
3.t= 2.23,~~ 0.05. 
4. t= 3.53.l,<o.o1. 
Since the PA group, who represented a greater percentage of caffeine-sensitive 
patients, had higher SCL-90-R scores in anxiety, somatization, and phobic anxiety 
than the non-PA group, the PA group was examined separately to eliminate possible 
effects due to diagnosis (Table 3). As was true of the total sample, there were no 
significant correlations between caffeine consumption and SCL-90-R scores and no 
Table 3. SCL-90-R differences between PA and non-PA groups 










Global severity index 
Positive symptom distress index 
PA group 
(n = 30) 
1.47 2 0.64 
1.70 L 0.76 
1.73 + 0.86 
2.02 t 0.76 
2.35 + 0.75 
1.12 k 0.86 
2.17 F 0.85 
1 .I4 t- 0.95 
0.98 k 0.60 
1.65 i 0.57 
2.34 F 0.55 
Non-PA group 
(n = 9) 
0.42 F 0.421 
1.43 + 0.84 
1.83 + 1.23 
1.73 I? 0.96 
1.58 ?I 1.112 
1.17 k 0.78 
1.03 + 0.85s 
1.15kO.66 
0.92 + 0.73 
1.24 ?I 0.69 
2.11 + 0.63 
1. f = 4.61,~ c 0.001 
2 t=2.41,p<0.05. 
3. t= 3 53.p < 0.01. 
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difference in mean SCL-90-R subscale scores between the < 100 mg and the > 100 mg 
group. However, even among PA patients only, anxiety subscale score differences 
persisted between the caffeine-sensitive and the caffeine-nonsensitive groups-being 
higher in the caffeine-sensitive group; but no differences in somatization or phobic 
anxiety were observed (Table 2). There were no differences in caffeine consumption or 
use of minor tranquilizers between these two PA groups. 
Comparison With Medical Inpatients. Both anxiety and medical inpatient groups 
were divided into three strata by using cutoff values of daily caffeine consumption 
similar to a prior report (Victor et al., 198 I): low consumer (O-249 mg/day), moderate 
consumer (250-749 mg/day), and high consumer (2 750 mg/day). Their distribution 
of caffeine consumption was significantly different (x2 = 23.37, p < 0.001). In the 
anxiety disorders group, 84% were low consumers, 14% were moderate consumers, 
and 2% were high consumers; in contrast, 41% of medical inpatients were low 
consumers, 43% were moderate consumers, and 16% were high consumers. Thus, 
anxious patients consumed significantly less caffeine. Age distribution, which has 
been reported to affect caffeine consumption (Victor et al., 1981) was not different 
between these groups. 
Since the majority of anxiety patients were low consumers, symptom profiles in 
response to drinking a cup of coffee were compared between anxious patients and 
medical inpatients for the low consumer groups only. Anxiety disorder patients 
reported a significantly higher rate of anxiety and tremulousness in response to coffee 
consumption compared to the medical inpatient group. No other symptoms were 
different in these groups (Table 1). 
Discussion 
Two-thirds of the anxiety patients in this study consumed < 100 mg of caffeine/day; 
when compared to medical inpatients, twice the number of anxiety patients consumed 
< 250 mg/day. This difference was not due to inpatient vs. outpatient status because 
questionnaires asked specifically about the amount of caffeine’consumption before 
admission to the hospital. This level of consumption was also less than that of 
previously reported psychiatric inpatients who were similar to the medical inpatient 
group (Victor et al., 1981). 
Among low caffeine consumers only, three times as many anxiety disorder patients 
as medical inpatients reported anxiety symptoms in response to coffee consumption. 
Thus, anxiety patients were more sensitive to caffeine than were medical inpatients, 
even though their daily caffeine consumption was in the same range. In this sample of 
anxiety patients, the SCL-90-R anxiety subscale score did not differ between high (> 
100 mg/day) and low (< 100 mg/day) caffeine consumers. However, anxiety level was 
different if compared according to patients’ratings of their response to drinking a cup 
of coffee; the caffeine-sensitive patients had higher SCL-90-R anxiety subscale scores 
than the caffeine-nonsensitive patients, even though the amount of daily caffeine 
consumption did not differ between the two groups. 
The difference in anxiety scores between caffeine-sensitive and nonsensitive patients 
seems not to be due to overrepresentation of PA patients in the caffeine-sensitive 
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group since, even if only PA patients are evaluated, this difference in anxiety in 
response to caffeine consumption still remained, suggesting that the caffeine-sensitive 
group does have a higher anxiety level than the caffeine-nonsensitive group. On the 
other hand, differences in somatization and phobic anxiety in the total sample did 
seem to be due to the greater percentage of PA patients in the caffeine-sensitive group. 
This finding is different from prior studies with college students (Gilliland and 
Andress, 1981) and psychiatric inpatients (Greden et al., 1978), where only moderate 
to high caffeine consumers had high levels of state and/ or trait anxiety. Also, unlike 
medical inpatients (Victor et al., 1981) and normal adults (Rapoport et al., 1981), our 
high consumers did not differ from low consumers in reporting anxiety in response to 
drinking coffee (although other somatic symptoms tended to develop more in low 
consumers, similar to previous reports). In other words, in anxiety patients, reporting 
of anxiety symptoms according to amount of caffeine consumption was different from 
medical inpatients or normal adults, while the reporting of somatic symptoms 
according to amount of caffeine consumption was the same. This pattern suggests that 
neurobiological mechanisms mediating anxiety may have increased sensitivity to 
caffeine, whereas mechanisms mediating somatic symptoms may not. It is noteworthy 
that more PA patients became anxious in response to caffeine than non-PA patients; 
this deserves further testing in a larger sample to examine whether increased sensitivity 
to caffeine is characteristic of panic disorder but not other anxiety disorder diagnoses. 
Boulenger et al. (1984) also reported increased sensitivity to caffeine in panic disorder 
but not in major depressive disorder. 
In contrast to Boulenger et al. (1984), we did not find any significant correlations 
between amount of caffeine consumption and any of the XL-90-R subscale scores, 
probably due at least in part to the narrow range of daily caffeine consumption in most 
of the anxious patients in this sample. Boulenger et al. (1984) suggested that increased 
sensitivity to caffeine in panic disorder may not be related to baseline level of anxiety 
since their depressed patients also had high anxiety levels but did not have increased 
sensitivity to caffeine. However, the present data comparing anxiety level between 
caffeine-sensitive and caffeine-nonsensitive patients in the PA group suggested that, 
within PA patients, a high baseline anxiety level was related to increased sensitivity to 
caffeine. This difference suggests that the mechanism producing anxiety in depressive 
disorders may not involve increased sensitivity to caffeine but that in panic disorder it 
may. This needs to be clarified with future studies. Amount of daily caffeine 
consumption and increased sensitivity to caffeine in these anxiety patients were 
consistent with prior results. 
The data of this study suggested that in normal adults or in psychiatric inpatients 
(Gilliland and Andress, 1981; Greden et al., 1978) caffeine may be one of the 
contributing factors that increases anxiety, but in anxiety disorder patients, caffeine is 
not one of the significant factors that accounts for their high level of anxiety; rather, 
high anxiety appears to deter anxious individuals from high caffeine consumption. 
This probably explains why most anxiety disorder patients were low caffeine 
consumers. Also, sensitivity to caffeine is not clearly related to amount of daily 
caffeine consumption, as is the case in normal adults and medical inpatients 
(Rapoport et al., 1981; Victor et al., 1981); rather, in anxiety disorders, their 
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underlying high anxiety level seems to produce high sensitivity to caffeine, even in low 
doses. Future studies with caffeine challenges using double-blind procedures should 
provide more precise and quantifiable evidence of the effects of caffeine on anxiety. 
Caffeine should provide a pharmacological probe with which to study further the 
pathophysiology of panic and other anxiety disorders. 
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